Therefore, it could be anticipated that METTL18 contributes to the progression of HER2-positive breast cancer; however, our clinical data indicate that METTL18 is not associated with the prognostic outcomes of HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast cancer.